Compare REX AI Equity Premium Income ETF (AIPI) vs Baxter International Inc (BAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Baxter International Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.37, while Baxter International Inc trades at $26.77 (market cap $14.27B). The key difference: Baxter International Inc pays a 0.14% dividend while REX AI Equity Premium Income ETF pays none, and Baxter International Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | BAX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $28.35 |
52-Week Low | $32.45 | $15.80 |
Market Cap | — | $14.27B |
Enterprise Value | — | $21.79B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI (REX AI Equity Premium Income ETF) trades at $37.41 with minimal daily movement (+0.19%). The ETF employs an option-writing strategy focused on AI-related equities, generating substantial weekly dividends averaging $0.24-0.26 per distribution. Technical indicators show mixed signals with bullish moving averages but overbought RSI levels. The fund's unique structure provides high income but faces sustainability concerns if AI market momentum falters.
AIPI offers exceptional yield potential through its weekly distribution model but carries structural risks including potential NAV erosion. The ETF's performance depends heavily on continued AI sector strength and effective options management. Investors should weigh the high income against the fund's capped upside and concentration in technology stocks during market volatility.
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
